Research Topics
Species | Hans Peter HornySummaryCountry: Germany Publications
| Collaborators
|
Detail Information
Publications
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findingsH P Horny
Institute of Pathology, Medical University of Lubeck, Ratzeburger Allee 160, D 23538 Lubeck, Germany
Leuk Res 25:543-51. 2001....
Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimensH P Horny
Institute of Pathology, University of Lubeck, D 23538 Lubeck, Germany
J Clin Pathol 56:575-8. 2003....- An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL)H P Horny
Institute of Pathology, University of Lubeck, Germany
J Clin Pathol 59:264-8. 2006..This report contributes to the differential diagnosis of ISM by demonstrating that such lymphocytic aggregates may be neoplastic... - Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric studyH P Horny
Institute of Pathology, University of Lubeck, Ratzeburger Allee 160, D 23538 Lubeck, Germany
J Clin Pathol 56:103-6. 2003..Tryptase is constitutively expressed by all MC, whereas chymase is found only in an MC subset. Very little is known about chymase expression in MC proliferative disorders (mastocytosis)... - [Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]Hans Peter Horny
Institut fur Pathologie, Medizinische Universität zu Lübeck MUL, Lubeck
Wien Klin Wochenschr 114:222-8. 2002.... - The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markersH P Horny
University of Lubeck, Institute of Pathology, Lubeck, Germany
J Clin Pathol 59:298-302. 2006.... - Histopathological and immunohistochemical aspects of mastocytosisHans Peter Horny
Institute of Pathology, Medical University of Lubeck, Germany
Int Arch Allergy Immunol 127:115-7. 2002..The demonstration of expression of vascular endothelial growth factor by mast cells is consistent with the finding of angiogenesis which is commonly seen in tissue infiltrates of mastocytosis... - Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challengeH P Horny
Institute of Pathology, University of Lubeck, D 23538 Lubeck, Germany
J Clin Pathol 57:604-8. 2004.... - Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemiaKarl Sotlar
Institute of Pathology, University of Tubingen, Liebermeisterstrasse 8, D 72076, Tubingen, Germany
Leuk Res 26:979-84. 2002.... - Mastocytosis: state of the artHans Peter Horny
Institute of Pathology, Ansbach, Germany
Pathobiology 74:121-32. 2007.... 
Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)Karl Sotlar
Institute of Pathology, University of Munich, Germany
J Pathol 220:586-95. 2010....- Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD8Karl Sotlar
Institute of Pathology, University of Tubingen, Liebermeisterstrasse 8, D 72076 Tubingen, Germany
J Mol Diagn 10:58-66. 2008..Altogether, these data suggest that KIT(D816V+) SM can co-exist with JAK2(V617F+) CIMF and that, in some of these SM-CIMF cases, the two mutations are present in the neoplastic cells of both disease components... - Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosisKarl Sotlar
Institute of Pathology, University of Munich, Munich, Germany
Mod Pathol 24:585-95. 2011..Upregulated expression of CD30 in advanced systemic mastocytosis may thus be employed as a potential marker for grading systemic mastocytosis in hematopathology... - One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probesKarl Sotlar
Institute of Pathology, University of Tubingen, Tubingen, Germany
Am J Pathol 162:737-46. 2003.... - Primary diagnosis of Whipple's disease in bone marrowStefan Martin Krober
Institute of Pathology, University of Tubingen, Tubingen, Germany
Hum Pathol 35:522-5. 2004.... - Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromesHans Peter Horny
Institute of Pathology, D 91522 Ansbach, Germany
Leuk Res 31:1609-16. 2007..Histologic/immunohistochemical investigation of the bone marrow therefore is strongly recommended for patients with (suspected) MDS, the minimum marker-panel suggested being CD31, CD34, and tryptase... - Application of novel tissue microarrays to investigate expression of tryptase, chymase and KIT protein in placental mast cellsFrank Noack
Department of Pathology, University Hospital Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
Arch Gynecol Obstet 272:223-8. 2005..Because little is known about the role of mast cells in the placenta, we investigated the number and expression of chymase, tryptase, and KIT protein in placental mast cells using newly developed tissue microarrays... - Expression of KIT (CD117) in renal cell carcinoma and renal oncocytomaStefan Kruger
Institute of Pathology, University of Schleswig Holstein, Campus Lubeck, Lubeck, Germany
Oncology 68:269-75. 2005..Our aim was to analyze KIT expression immunohistochemically in renal cell carcinomas (RCCs) and in oncocytomas... - Adult hypocellular acute leukaemia with lymphoid differentiationStefan Martin Krober
Institute of Pathology, University of Tubingen, D 72076, Tubingen, Germany
Leuk Lymphoma 44:1797-801. 2003..The clinical course appears to be similar to that of hypocellular AML, as neither patient has developed overt leukemia during the one-year follow-up period... - Primary extranodal NK/T cell lymphoma ("nasal type") of the endometrium: report of an unusual case diagnosed at autopsyJuliane Briese
Department of Gynaecopathology, Institute of Pathology, University Clinic, Martinistrasse 52, DE 20246 Hamburg, Germany
Gynecol Obstet Invest 61:164-6. 2006..Primary natural killer (NK)/T cell lymphoma of the female genital tract is extremely rare. We here report the case of a "nasal type" NK/T cell lymphoma arising in the uterus. The diagnosis was established only at autopsy... - Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816VFrank Noack
Department of Pathology, University of Luebeck, Luebeck, Germany
Leuk Lymphoma 45:2295-302. 2004..However, additional (but yet unknown) molecular (genetic) defects have to be considered to explain the extremely heterogenous clinical course in these patients... - Lethal outcome in xanthogranulomatous endometritisFrank Noack
Department of Pathology, University Clinic Schleswig Holstein, Campus Lubeck, Lubeck, Germany
APMIS 114:386-8. 2006..Because this condition may mimic malignant disease macroscopically and histologically, knowledge of XE is of major importance for both pathologists and gynecologists... - Myocardial infarction as an uncommon clinical manifestation of intravascular large cell lymphomaAlexander Bauer
Dept of Internal Medicine I, University of Lubeck, Germany
Acta Cardiol 60:551-5. 2005..To the best of the authors' knowledge myocardial infarction as a leading symptom of IVL has not been described... - Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cellsHans Peter Horny
Institute of Pathology, D 91522 Ansbach, Germany
Am J Clin Pathol 132:438-47. 2009..Expression of CD25 on mast cells is defined as a minor diagnostic criterion and is usually seen only in mastocytosis but not in reactive states of mast cell hyperplasia... - Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disordersHermine Agis
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Am J Clin Pathol 125:273-81. 2006..In summary, BB1 (basogranulin) is a new immunohistochemical basophil marker that should allow quantification of basophils in CML at diagnosis and during therapy... - Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasiaManuela Krokowski
Institute of Pathology, , , Germany
Am J Clin Pathol 124:560-8. 2005..Our data show that the infiltration pattern in SM correlates with the disease subtype and should be recognized as an important aspect in the histomorphologic evaluation of the bone marrow... - Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cellsPeter Valent
Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
Hematol J 3:90-4. 2002..In the few patients recorded so far, a complex karyotype without recurring anomaly was found. The prognosis appears to be grave, although complete remission in response to chemotherapy has been described... - Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosisHermine Agis
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
Leuk Res 29:1227-32. 2005..The exact knowledge of the pathology and target-profile of the associated leukemias in SM have important therapeutic implications... - Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosisMaria-Theresa Krauth
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
Hum Pathol 37:439-47. 2006..Histidine decarboxylase should therefore be considered as a new MC marker in the screen panel of antigens used to diagnose high-grade MC malignancies... - Mast cell proliferative disorders: current view on variants recognized by the World Health OrganizationPeter Valent
Department of Internal Medicine 1, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, Vienna, Austria
Hematol Oncol Clin North Am 17:1227-41. 2003..In patients with SM-AHNMD, the SM should be treated as if no AHNMD is present, and the AHNMD should be treated as if no SM had been diagnosed... - Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB categoryMinoo Ghannadan
Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
Am J Clin Pathol 119:663-71. 2003..In summary, VEGF expression in the bone marrow is restricted to certain stages of differentiation and maturation of myeloid cells and correlates with the FAB category... - Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcomaAndreas Chott
Department of Pathology, University of Vienna, Vienna, Austria
Am J Surg Pathol 27:1013-9. 2003..Together, neoplastic mast cells in a case of mast cell sarcoma were found to exhibit unique morphologic, phenotypical, and molecular features when compared with mast cells in indolent mastocytosis or normal tissue mast cells... - Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of diseaseWolfgang R Sperr
Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
Int Arch Allergy Immunol 128:136-41. 2002..The serum tryptase level is used as a diagnostic marker in mastocytosis and is considered to reflect the burden of (neoplastic) mast cells (MC)... - Splenic mastocytosis: report of two cases and detection of the transforming somatic C-KIT mutation D816VFriedrich Wimazal
Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Vienna, Austria
Leuk Lymphoma 45:723-9. 2004..In summary, our data show that the spleen can be a primary site of disease in rare cases of SM. Mastocytosis should therefore be considered as a (rare) differential diagnosis in patients with splenomegaly of unknown etiology... - Bone marrow mastocytosis associated with IgM kappa plasma cell myelomaFlorian Stellmacher
Institute of Pathology, , Ratzeburger Allee 160, D-23538, , Germany
Leuk Lymphoma 45:801-5. 2004.... - Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteriaJohn-Hendrik Jordan
Department of Internal Medicine 1, University of Vienna, , Austria
Leuk Lymphoma 43:575-82. 2002..Based on our case and similar cases mimicking mastocytosis, it seems of importance to apply recently established SM criteria in order to discriminate between reactive MC hyperplasia and true mastocytosis with certainty... - Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasmsPeter Valent
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
J Allergy Clin Immunol 114:3-11; quiz 12. 2004..The current review provides an overview of mastocytosis and its subvariants and a practical guide that might help to delineate mastocytosis from unrelated systemic disorders... - CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimensKarl Sotlar
Institute of Pathology, , , Germany
Am J Surg Pathol 28:1319-25. 2004..CD25 therefore appears to be a reliable immunohistochemical marker for the discrimination of neoplastic from normal/reactive MCs, with potential as a diagnostic tool in SM... - Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosisMartin Anlauf
Department of Pathology, University of Kiel, Michaelisstr 11, 24105 Kiel, Germany
J Histochem Cytochem 54:201-13. 2006.... - Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodesStefan Florian
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Int Arch Allergy Immunol 136:273-80. 2005..Finally, our case further shows that mastocytosis can be an important differential diagnosis to be considered in patients with unexplained anaphylactoid or other mediator-related symptoms... - Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosisWolfgang R Sperr
Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria
Int Arch Allergy Immunol 127:140-2. 2002..No general guidelines for the treatment of patients with SM-AHNMD have been established so far. A reasonable straightforward approach may be to treat the AHNMD in those patients in the same way as if no coexisting SM exists... - Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemiaPeter Valent
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Leuk Lymphoma 49:635-8. 2008..Application of these markers may assist in determining the phase of disease and may help to better predict the prognosis in individual patients... - Sustained remission of an extensive monoclonal, Epstein-Barr virus-associated diffuse large B cell lymphoma in a kidney-pancreas transplant recipientMarkus G Manz
Department of Medicine II, Eberhard-Karls-University, , Germany
Transplantation 73:995-7. 2002..Infection with two individual EBV strains earlier in life may increase the number of specific CTL clones and increase the memory capacity... - Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaPeter Valent
Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
Leuk Res 27:635-41. 2003..This confirms clinical activity in some patients for this drug-combination, but also points to the need to search for more effective strategies in the treatment of patients with aggressive mast cell disorders... - Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferencePeter Valent
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
Leuk Res 31:727-36. 2007..Respective algorithms and recommendations should facilitate diagnostic and prognostic evaluations in MDS, selection of patients for therapies, and the conduct of clinical trials... - The European Competence Network on Mastocytosis (ECNM)Peter Valent
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
Wien Klin Wochenschr 116:647-51. 2004..In addition, the ECNM is dedicated to provide the best available information about the disease to patients and physicians... - Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemiaWolfgang Füreder
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1097 Vienna, Austria
Am J Pathol 168:123-30. 2006..05). Taken together, these data show that aplastic anemia is associated with reduced angiogenesis and reduced VEGF expression... - ReviewHans-Peter Horny
, , Germany
Clin Adv Hematol Oncol 2:752. 2004 - Mastocytosis: pathology, genetics, and current options for therapyPeter Valent
Department of Internal Medicine I, Medical Univeristy of Vienna, Austria
Leuk Lymphoma 46:35-48. 2005..Examples include the use of STI571 in patients with SM plus hypereosinophilic syndrome (SM-HES) and the FIPL1/PDGFRA fusion gene target, or chemotherapy for eradication of AML in patients with SM-AML... - Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemiaOlaf Penack
Ann Hematol 84:692-3. 2005 - Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progressionPeter Valent
Department of Internal Medicine I, Division of Hematology, University of Vienna, Austria
Int Arch Allergy Immunol 127:137-9. 2002..In the present article, we discuss clinical and laboratory findings in smouldering SM and review the current literature. In addition, the pathophysiology of this novel subtype of SM is discussed...